GlassScriptPhysician profile
Ahmad Rafeek Farah
NPI 1285730531
$10,003.24
in general payments reported to CMS, 2019-2025
34 companies · $3,393 in 2025
The $3,393 reported for 2025 was more than what 90% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $244 · 2021: $1,644 · 2022: $1,836 · 2023: $683 · 2024: $1,797 · 2025: $3,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,235 · Food and Beverage: $2,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,234.50 |
| Food and Beverage | $2,638.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle, INC | $2,645.60 | 2022-2025 | |
| Arthrex, INC. | $2,181.20 | 2024-2025 | |
| Anika Therapeutics, INC. | $1,332.59 | 2021-2023 | Tactoset, Toe Motion |
| Medical Device Business Services, INC. | $807.08 | 2024 | |
| Stryker Corporation | $733.50 | 2019-2025 | Flexband Plus, Easyfuse, Flexband |
| Janssen Pharmaceuticals, INC | $304.37 | 2020-2022 | |
| Depuy Synthes Sales INC. | $289.36 | 2020-2024 | Na, Motoband, Minibunion |
| Medtronic, INC. | $254.48 | 2022-2025 | Venaseal, Intellis Adaptivestim |
| Horizon Therapeutics Plc | $234.95 | 2021-2023 | Tepezza, Krystexxa |
| Organogenesis INC. | $188.47 | 2022-2025 | Puraply Antimicrobial, Puraply Wound Matrix, Apligraf |
| Integra Lifesciences Corporation | $186.34 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $123.68 | 2019-2021 | |
| Boston Scientific Corporation | $121.94 | 2025 | General - Pain Management |
| Orthofix Medical, INC. | $62.91 | 2019-2025 | Physio-Stim |
| Davol INC. | $59.57 | 2025 | Surgiphor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $57.61 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Paragon 28, INC. | $46.92 | 2019-2023 | Additive Orthopedics |
| Pfizer INC. | $41.16 | 2019-2020 | |
| Averitas Pharma INC. | $41.15 | 2023 | Qutenza |
| Zimmer Biomet Holdings, INC. | $34.24 | 2021-2022 | |
| Linvatec Corporation | $24.89 | 2021 | |
| Cardiovascular Systems INC. | $24.62 | 2019 | |
| Nabriva Therapeutics, Plc | $23.76 | 2022 | |
| Abbott Laboratories | $22.89 | 2023 | Proclaim |
| Convatec INC. | $21.24 | 2022 | |
| Heron Therapeutics, INC. | $20.85 | 2024 | Zynrelef |
| Amgen INC. | $18.01 | 2024 | Krystexxa |
| Axogen | $16.29 | 2021 | |
| Osteomed LLC | $15.49 | 2021 | |
| Merck Sharp & Dohme LLC | $14.65 | 2019 | |
| Next Science LLC | $14.18 | 2023 | Xperience, Blastx, Surgx |
| Trice Medical, INC. | $13.83 | 2023 | |
| Paratek Pharmaceuticals, INC. | $12.74 | 2021 | |
| Grt US Holding, INC. | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Farah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.